ORN0829

short T1/2 dual orexin 1/2 receptor antagonist

in clinical dev. for insomnia (Ph. II)

from ligand-based drug design

Bioorg. Med. Chem., Apr. 11, 2020

Taisho Pharmaceutical Co., Saitama, JP

ORN0829 is a dual inhibitor of orexins 1 and 2, designed to have a relatively short half life in humans for application in insomnia (to reduce side effects after waking…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.